IDT expands global footprint with launch of China office

Coralville-based Integrated DNA Technologies (IDT) has announced the launch of IDT China, an official business entity to be headquartered in Shanghai.

The genomics solutions provider said the launch is the latest step in IDT’s ongoing global expansion to support researchers across numerous disciplines from pharmaceutical development to agricultural biology. IDT has facilities in Asia, Europe and North America, and serves customers in more than 100 countries.

“The launch of IDT China better positions our team to provide localized support and enable important research projects throughout the region,” said IDT President Trey Martin in a release. “China has experienced significant growth in life sciences research, becoming a leader in the pursuit of new technologies for translational and personalized medicine, and we look forward to enabling their activities.”

IDT made national headlines earlier this year, as the coronavirus pandemic took hold, by becoming the first U.S. company to have its primer and probe kits approved by the U.S. Centers for Disease Control and Prevention for use in its COVID-19 testing protocol.

IDT officials said the launch of IDT China allows it to better serve its customer base in the region, reach new customers and provide easier access to its complete portfolio of industry-leading products. IDT products include a robust next generation sequencing (NGS) product portfolio that provides tools to support growing research efforts in China to develop precision medicine.

The new office continues IDT’s partnerships in China aimed at increasing support of research projects, including the establishment of a strategic collaboration last year with Chinese medical sequencing firm ChosenMed. IDT’s work with ChosenMed includes providing its market-leading NGS enrichment products for cancer sequencing studies. The two companies are also developing large pan-cancer research panels as part of the Cancer Atlas of China (CGAC) project, which is focused on the future of Chinese cancer diagnosis.